Phase I clinical study of irinotecan (CPT-11) in combination with UFT/folinic acid (FA) in patients with advanced colorectal cancer (CRC).

被引：0
|
作者：
Paz-Ares, L
Garcia-Alfonso, P
Castellanos, D
Martin, B
Perez-Manga, G
Cortes-Funes, H
Gonzalez, J
Gravalos, C
机构：
[1] Univ Madrid, Hosp Doce Octubre, Madrid 3, Spain
[2] Hosp Gen Gregorio Maranon, Madrid, Spain
[3] Aventis, Madrid, Spain
来源：
CLINICAL CANCER RESEARCH | 2000年 / 6卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
543
引用
收藏
页码：4575S / 4575S
页数：1
相关论文
共 50 条
  • [31] Irinotecan (CPT-11) pretreated metastatic colorectal cancer (CRC):: A single institution experience.
    Fernández, Y
    Lara, MA
    Salinas, P
    Alonso, ML
    García-Girón, C
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S12 - S12
  • [32] Phase I/II study of irinotecan and UFT for advanced or metastatic colorectal cancer
    Mibu, R.
    Tanaka, S.
    Futami, K.
    Shimada, K.
    Hotokezaka, M.
    Nakahara, S.
    Ichimiya, H.
    Kido, H.
    Hirano, Y.
    Kashiwagi, T.
    Eguchi, T.
    Mitsuki, K.
    Mizumoto, K.
    Tanaka, M.
    ANTICANCER RESEARCH, 2007, 27 (4C) : 2673 - 2677
  • [33] A phase I/II study of tegafur-uracil (UFT) plus oral leucovorin (LV) and biweekly CPT-11 therapy for patients (pts) with metastatic colorectal cancer (CRC).
    Uetake, H
    Tetsuro, H
    Enomoto, M
    Sugihara, K
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 303S - 303S
  • [34] Phase I/II study of CPT-11 plus UFT in patients with advanced/recurrent colorectal cancer: Osaka gastrointestinal cancer chemotherapy study group (OGSG): Protocol 0102
    Tomita, Naohiro
    Fukunaga, Mutsumi
    Okamura, Shu
    Narahara, Hiroyuki
    Uedo, Noriya
    Ishihara, Ryu
    Ishida, Hideyuki
    Furukawa, Hiroshi
    Gotoh, Masahiro
    Takiuchi, Hiroya
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (07) : 521 - 527
  • [35] Weekly irinotecan (CPT-11) as a single agent, in heavily pretreated patients with advanced colorectal cancer (CRC) and low performance status (PS).
    Benavides, M
    Alfonso, PG
    Cobo, M
    Graupera, J
    Muñoz, MD
    Carabantes, F
    Molina, M
    Gil, S
    Balcells, M
    Perez-Manga, G
    ANNALS OF ONCOLOGY, 2000, 11 : 44 - 44
  • [36] Phase I/II study of 24-hour infusion of irinotecan (CPT-11) in combination with sequential oral leucovorin (LV) and uracil/tegafur (UFT) for patients (PTS) with metastatic colorectal cancer (MCRC)
    Sadahiro, Sotaro
    Maeda, Yuji
    Suzuki, Toshiyuki
    Makuuchi, Hiroyasu
    Kamijo, Akemi
    Murayama, Chieko
    ANNALS OF ONCOLOGY, 2006, 17 : 117 - 117
  • [37] Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002)
    Takiuchi, H
    Narahara, H
    Tsujinaka, T
    Gotoh, M
    Kawabe, S
    Katsu, K
    Iishi, H
    Tatsuta, M
    Fujitani, K
    Furukawa, H
    Taguchi, T
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (09) : 520 - 525
  • [38] A Phase I dose escalation study of selenomethionine (SLM) in combination with fixed dose irinotecan (CPT-11) in patients with advanced solid tumors
    Fakih, Marwan G.
    Pendyala, Lakshmi
    Creaven, Patrick J.
    Smith, Patrick
    Ross, Mary Ellen
    Rustum, Youcef
    CANCER RESEARCH, 2006, 66 (08)
  • [39] A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer
    Hotta, K
    Ueoka, H
    Kiura, K
    Tabata, M
    Kuyama, S
    Satoh, K
    Kozuki, T
    Hisamoto, A
    Hosokawa, S
    Fujiwara, K
    Tanimoto, M
    LUNG CANCER, 2004, 45 (01) : 77 - 84
  • [40] Phase I dose finding study with irinotecan (CPT-11) in cancer patients (pts) with hepatic dysfunction
    Raymond, E
    Vernillet, L
    Boige, V
    Hua, A
    Ducreux, M
    Mekhaldi, S
    Jacques, C
    Gatineau, M
    Mignard, D
    Vergniol, JC
    Armand, JP
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S283 - S284
12345